Antibiotics duration guided by biomarkers in hospitalized adult patients; a systematic review and meta-analysis

References

• CDC. Core elements of hospital antibiotic stewardship programs. Atlanta (GA): US Department of Health and Human Services, CDC; 2019. Available from: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html
   Google Scholar
• NCI dictionary of cancer terms [Internet]. National Cancer Institute; 2021 [cited 2021 Jun 4]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
   Google Scholar
• Mehanic S, Baljic R. The importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsis. Mater Sociomed. 2013;25(4):277–281.
   PubMedGoogle Scholar
• Sproston N, Ashworth J. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:9.
   PubMed Web of Science ®Google Scholar
• Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available from: www.covidence.org
   Google Scholar
• Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.
   Google Scholar
• McGrath S, Zhao XF, Steele R, et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29(9):2520–2537.
   PubMed Web of Science ®Google Scholar
• Annane D, Maxime V, Faller JP, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open. 2013;3(2):e002186.
   PubMed Web of Science ®Google Scholar
• Borges I, Carneiro R, Bergo R, et al. Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers. Crit Care. 2020;24(1):281.
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–474.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.
   PubMed Web of Science ®Google Scholar
• Corti C, Fally M, Fabricius-Bjerre A, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. COPD. 2016;11(1):1381–1389.
   Google Scholar
• Daubin C, Valette X, Thiollière F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med. 2018;44(4):428–437.
   PubMed Web of Science ®Google Scholar
• de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–827.
   PubMed Web of Science ®Google Scholar
• Deliberato RO, Marra AR, Sanches PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis. 2013;76(3):266–271.
   PubMed Web of Science ®Google Scholar
• Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int J Med Sci. 2013;10(7):903–907.
   PubMed Web of Science ®Google Scholar
• Drozdov D, Schwarz S, Kutz A, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Med. 2015;13(1):104.
   PubMed Web of Science ®Google Scholar
• Hochreiter M, Köhler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13(3):R83.
   PubMed Web of Science ®Google Scholar
• Jeon K, Suh JK, Jang EJ, et al. Procalcitonin-guided treatment on duration of antibiotic therapy and cost in septic patients (PRODA): a multi-center randomized controlled trial. J Korean Med Sci. 2019;34(14):e110.
   PubMed Web of Science ®Google Scholar
• Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med. 2021;203(2):202–210.
   PubMed Web of Science ®Google Scholar
• Lima SSS, Nobre V, de Castro Romanelli RM, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol. 2016;95(7):1169–1176.
   PubMed Web of Science ®Google Scholar
• Montassier E, Javaudin F, Moustafa F, et al. Guideline-based clinical assessment versus procalcitonin-guided antibiotic use in pneumonia: a pragmatic randomized trial. Ann Emerg Med. 2019;74(4):580–591.
   PubMed Web of Science ®Google Scholar
• Nobre V, Harbarth S, Graf J-D, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505.
   PubMed Web of Science ®Google Scholar
• Ogasawara T, Umezawa H, Naito Y, et al. Procalcitonin-guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respir Investig. 2014;52(2):107–113.
   PubMedGoogle Scholar
• Qu R, Ji Y, Ling Y, et al. Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis: a randomized prospective single-center controlled trial. Saudi Med J. 2012;33(4):382–387.
   PubMed Web of Science ®Google Scholar
• Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009;394(2):221–226.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. J Am Med Assoc. 2009;302(10):1059–1066.
   PubMed Web of Science ®Google Scholar
• Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med. 2014;190(10):1102–1110.
   PubMed Web of Science ®Google Scholar
• Slieker JC, Aellen S, Eggimann P, et al. Procalcitonin-guided antibiotics after surgery for peritonitis: a randomized controlled study. Gastroenterol Res Pract. 2017;2017:1–6.
   Web of Science ®Google Scholar
• Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009;34(6):1364–1375.
   PubMed Web of Science ®Google Scholar
• Verduri A, Luppi F, D’Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLOS One. 2015;10(3):e0118241.
   PubMed Web of Science ®Google Scholar
• Vishalashi SMG, Gupta P, Verma PK. Serum procalcitonin as a biomarker to determine the duration of antibiotic therapy in adult patients with sepsis and septic shock in intensive care units: a prospective study. Indian J Crit Care Med. 2021;25(5):507–511.
   PubMed Web of Science ®Google Scholar
• von Dach E, Albrich WC, Brunel A-S, et al. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. JAMA. 2020;323(21):2160–2169.
   PubMed Web of Science ®Google Scholar
• Mazlan MZ, A H Ismail M, Ali S, et al. Efficacy and safety of the point-of-care procalcitonin test for determining the antibiotic treatment duration in patients with ventilator-associated pneumonia in the intensive care unit: a randomised controlled trial. Anaesthesiol Intensive Ther. 2021;53:207–214.
   PubMed Web of Science ®Google Scholar
• Wirz Y, Meier M, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191.
   PubMedGoogle Scholar
• Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.
   PubMed Web of Science ®Google Scholar
• Petel D, Winters N, Gore G, et al. Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis. BMJ Open. 2018;8(12):e022133.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Botoni F, Oliveira C, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis. Crit Care Med. 2013;41(10):2336–2343.
   PubMed Web of Science ®Google Scholar